Search Resources (English): Women and Health Protection (WHP)

Results 11 - 20 of 63

Results

Inclusion of women in clinical trials: therapeutic products programme guidelines  
http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/guides/clintrls/wominct_e.html

Details guidelines to ensure that women are enrolled in clinical trials at all stages of drug development in order to define the risks and benefits associated with drug therapy.

 (See Details)
Published: 1997
Drug regulatory failure in Canada: the case of Diane-35  
http://www.whp-apsf.ca/en/documents/diane35.html

Criticizes federal prescription drug regulation using Diane-35 (cyproterone acetate and ethinyl estradiol) as an example.

 (See Details)
Published: 2004
The marketization of depression: the prescribing of SSRI antidepressants to women  
http://www.whp-apsf.ca/pdf/SSRIs.pdf

Looks at the impact of SSRI use among Canadian women. Reviews what is currently known about the benefits and harms caused by SSRIs, as well as both the definition and incidence of depression in women.

 (See Details)
Published: 2005
Transparency and the drug approval process at Health Canada: policy brief  
http://www.whp-apsf.ca/en/documents/trans_policy.html

Argues that the lack of transparency in the drug approval process can lead to inappropriate, unnecessary and sometimes dangerous drug use, and it impedes the development of knowledge and appropriate decision-making.

 (See Details)
Published: 2006
To do no harm: why women are concerned about the dismantling of Health Protection Legislation in Canada  
http://www.whp-apsf.ca/en/documents/no_harm.html

Presents the position of participating women's health and consumer groups regarding Health Canada's proposed overhaul of federal health protection legislation.

 (See Details)
Published: 1998
Direct-to-consumer prescription drug advertising: when public health is no longer a priority  
http://www.whp-apsf.ca/en/documents/dtca_priority.html

Discusses the problems with direct-to-consumer advertising of prescription drugs and the impacts that such illegal promotion can have on women, especially given the unnecessary medicalization women face. Provides information on Canada's Food and Drug Act that prohibits advertising of prescription drugs directed to the general public and looks at the new federal project, the Health Protection Act, which would introduce some form of direct-to-consumer advertising. (See Details)

Published: 2001
Direct-to-consumer advertising of prescription drugs  
http://www.whp-apsf.ca/en/documents/dtca.html

Outlines concerns about direct-to-consumer advertising, including lack of public regulation and targeting of already healthy populations.

 (See Details)
Published: 1999
International harmonisation of pharmaceuticals: key issues of concern for public health  
http://www.whp-apsf.ca/en/documents/harmon.html
Focuses on the activities and implications of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Identifies specific areas of concern for public health and the public interest in the realisation of health. (See Details)
Published: 2001
The inclusion of women in clinical trials: are we asking the right questions?  
http://www.whp-apsf.ca/pdf/clinicalTrialsEN.pdf
Addresses the issues evoked in considering the inclusion of women in clinical trials, highlighting especially where gender, even more than sex, is pertinent. (See Details)
Published: 2006
Women's cycles up for sale: neo-medicalization and women's reproductive health  
http://www.cwhn.ca/node/39520
Examines the medicalization of women's reproductive functions, including treating normal health cycles as problems or illnesses. (See Details)
Published: 2004